FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068641163> ?p ?o ?g. }

• W2068641163 endingPage "157" @default.
• W2068641163 startingPage "147" @default.
• W2068641163 abstract "The activity of the renin-angiotensin-aldosterone system (RAAS) is elevated both in the circulation and in the renal tissue of diabetic and nondiabetic nephropathies. The increased RAAS activity plays an important role in the hemodynamic and nonhemodynamic pathogenetic mechanisms involved in kidney disease. Previous studies have demonstrated that albuminuria is not only a marker of glomerular lesions, but also a progression promoter, and finally a powerful predictor of the long-term beneficial effect of blood pressure-lowering therapy. Randomized crossover and parallel blind studies in patients with diabetic nephropathy have demonstrated that angiotensin II receptor blockers (ARB) induce favorable changes in systemic blood pressure, renal hemodynamics, and proteinuria similar to those induced by angiotensin-converting enzyme (ACE) inhibition. Studies have revealed the optimal renoprotective dose for some ARBs; however, additional dose titration studies are urgently needed to obtain the maximum benefit of this valuable new class of compounds. The combination of ARB and ACE inhibition is well tolerated and even more effective than monotherapy in reducing systemic blood pressure and albuminuria in diabetic nephropathy. In addition, dual RAAS blockade is safe and well tolerated. Impaired autoregulation of glomerular filtration rate (GFR); demonstrated with some blood pressure-lowering agents implies disturbances in the downstream transmission of the systemic blood pressure into the glomerulus, leading to capillary hypertension or hypotension depending of the level of blood pressure. ARB does not interfere with GFR autoregulation in hypertensive diabetic patients. In contrast to previous observational studies with ACE inhibition, long-term treatment with ARB has similar beneficial renoprotective effect on progression of diabetic kidney disease in hypertensive diabetic patients with ACE II and DD genotypes. ARB can prevent/delay development of diabetic nephropathy independently of its beneficial blood pressure-lowering effect in patients with type 2 diabetes and microalbuminuria. Recently, two landmark studies led to the following conclusion: “Losartan and Irbesartan conferred significant renal benefit in patients with type 2 diabetes and nephropathy. This protection is independent of the reduction in blood pressure it causes. The ARB is generally safe and well tolerated.” A recent metaanalysis indicates that ARBs reduce cardiovascular events mainly because of reduction in first hospitalization for congestive heart failure in hypertensive type 2 diabetic patients with albuminuria. The studies mentioned here suggest that ARB represents a beneficial treatment of hypertension and proteinuria in incipient and overt diabetic nephropathy." @default.
• W2068641163 created "2016-06-24" @default.
• W2068641163 creator A5033215700 @default.
• W2068641163 creator A5041442093 @default.
• W2068641163 creator A5044496367 @default.
• W2068641163 creator A5047972825 @default.
• W2068641163 creator A5066391510 @default.
• W2068641163 creator A5070884818 @default.
• W2068641163 creator A5077987218 @default.
• W2068641163 creator A5083703658 @default.
• W2068641163 date "2004-03-01" @default.
• W2068641163 modified "2023-10-16" @default.
• W2068641163 title "Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points" @default.
• W2068641163 cites W1972492725 @default.
• W2068641163 cites W1983956013 @default.
• W2068641163 cites W1988334849 @default.
• W2068641163 cites W1992573754 @default.
• W2068641163 cites W1992719998 @default.
• W2068641163 cites W2001049748 @default.
• W2068641163 cites W2003895389 @default.
• W2068641163 cites W2005718118 @default.
• W2068641163 cites W2010334178 @default.
• W2068641163 cites W2020267369 @default.
• W2068641163 cites W2024635091 @default.
• W2068641163 cites W2033665979 @default.
• W2068641163 cites W2033905400 @default.
• W2068641163 cites W2039880240 @default.
• W2068641163 cites W2042708695 @default.
• W2068641163 cites W2044276013 @default.
• W2068641163 cites W2044773944 @default.
• W2068641163 cites W2045161455 @default.
• W2068641163 cites W2045279107 @default.
• W2068641163 cites W2045790461 @default.
• W2068641163 cites W2049276892 @default.
• W2068641163 cites W2056976690 @default.
• W2068641163 cites W2059346848 @default.
• W2068641163 cites W2061475731 @default.
• W2068641163 cites W2061546662 @default.
• W2068641163 cites W2066538838 @default.
• W2068641163 cites W2074172534 @default.
• W2068641163 cites W2075391935 @default.
• W2068641163 cites W2081864124 @default.
• W2068641163 cites W2082790691 @default.
• W2068641163 cites W2083008696 @default.
• W2068641163 cites W2084343172 @default.
• W2068641163 cites W2091262290 @default.
• W2068641163 cites W2091698284 @default.
• W2068641163 cites W2097845189 @default.
• W2068641163 cites W2098154750 @default.
• W2068641163 cites W2104158979 @default.
• W2068641163 cites W2106146348 @default.
• W2068641163 cites W2107656189 @default.
• W2068641163 cites W2111726814 @default.
• W2068641163 cites W2117622300 @default.
• W2068641163 cites W2125316810 @default.
• W2068641163 cites W2126045082 @default.
• W2068641163 cites W2128122485 @default.
• W2068641163 cites W2132119176 @default.
• W2068641163 cites W2132881011 @default.
• W2068641163 cites W2133217116 @default.
• W2068641163 cites W2137946319 @default.
• W2068641163 cites W2139634859 @default.
• W2068641163 cites W2140172772 @default.
• W2068641163 cites W2141120643 @default.
• W2068641163 cites W2143144750 @default.
• W2068641163 cites W2144042768 @default.
• W2068641163 cites W2146732398 @default.
• W2068641163 cites W2152280966 @default.
• W2068641163 cites W2160541810 @default.
• W2068641163 cites W2161542391 @default.
• W2068641163 cites W2261053353 @default.
• W2068641163 cites W2615684303 @default.
• W2068641163 cites W3021250193 @default.
• W2068641163 cites W3156148333 @default.
• W2068641163 cites W4234761423 @default.
• W2068641163 cites W4237930539 @default.
• W2068641163 cites W4245133279 @default.
• W2068641163 cites W4252423764 @default.
• W2068641163 doi "https://doi.org/10.1016/j.semnephrol.2003.11.003" @default.
• W2068641163 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15017527" @default.
• W2068641163 hasPublicationYear "2004" @default.
• W2068641163 type Work @default.
• W2068641163 sameAs 2068641163 @default.
• W2068641163 citedByCount "56" @default.
• W2068641163 countsByYear W20686411632012 @default.
• W2068641163 countsByYear W20686411632013 @default.
• W2068641163 countsByYear W20686411632014 @default.
• W2068641163 countsByYear W20686411632015 @default.
• W2068641163 countsByYear W20686411632016 @default.
• W2068641163 countsByYear W20686411632018 @default.
• W2068641163 countsByYear W20686411632019 @default.
• W2068641163 countsByYear W20686411632020 @default.
• W2068641163 countsByYear W20686411632021 @default.
• W2068641163 countsByYear W20686411632022 @default.
• W2068641163 countsByYear W20686411632023 @default.
• W2068641163 crossrefType "journal-article" @default.
• W2068641163 hasAuthorship W2068641163A5033215700 @default.
• W2068641163 hasAuthorship W2068641163A5041442093 @default.

• next